PROTEASE INHIBITOR (PI)
Reyataz is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in combination with other antiretroviral medications in people three months or older. Reyataz is also referred to by its drug name, Atazanavir, and by the abbreviation ATV. Atazanavir is a component of the combination drug Evotaz.
Reyataz is an antiviral medication of the protease inhibitor (PI) class. Reyataz is believed to work by preventing HIV from replicating in cells.
How do I take it?
Prescribing information states that Reyataz is taken once or twice daily.
Reyataz comes in capsule and oral powder forms.
The FDA-approved label for Reyataz lists common side effects including headache, nausea, vomiting, diarrhea, stomach pain, fatigue, fever, numbness or pain in the hands and feet, depression, dizziness, insomnia, and changes in the shape or location of body fat.
Rare but serious side effects listed for Reyataz include severe skin reactions and jaundice.
For more details about this treatment, visit:
Reyataz – RxList
Overview of HIV Treatments – AIDS.gov